Tech Center 1600 • Art Units: 1638
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18546221 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | Non-Final OA | The Johns Hopkins University |
| 17704539 | WOUND TREATMENTS AND METHODS OF STABILIZING, PROTECTING, AND TREATING A WOUND | Final Rejection | Coloplast A/S |
| 18241669 | METHODS OF DETERMINING PROTEIN REDUCTION SUSCEPTABILITY | Non-Final OA | Sanofi |
| 18304472 | GENE THERAPEUTICS FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | Non-Final OA | University of Massachusetts |
| 18578247 | PRODUCTION METHOD OF FRAGMENTED EXTRACELLULAR MATRIX COMPONENT | Non-Final OA | OSAKA UNIVERSITY |
| 18290436 | CARTILAGE MODEL AS A SUBSTITUTE FOR ANIMAL MODELS AND METHODS FOR EVALUATING EFFECTIVENESS OR TOXICITY OF DRUGS USING THE SAME | Non-Final OA | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
| 18262224 | EAR CARTILAGE TISSUE ENGINEERING COMPLEX AND USE THEREOF | Non-Final OA | SHANGHAI NINTH PEOPLE'S HOSPITAL, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE |
| 17998553 | IMPROVED LENTIVIRAL EXPRESSION VECTOR, CONSTRUCTION METHOD FOR SAME, AND APPLICATIONS THEREOF | Non-Final OA | NANJING GENSCRIPT BIOTECH CO., LTD. |
| 17782544 | DEFECTIVE INTERFERING PARTICLES | Final Rejection | The Council of the Queensland Institute of Medical Research |
| 18569150 | DNA ORIGAMI SUBUNITS AND THEIR USE FOR ENCAPSULATION OF FILAMENTOUS VIRUS PARTICLES | Non-Final OA | University of Massachusetts Amherst |
| 18559119 | Methods for Making Stem Cell-Derived Enteric Neural Crest Cells and Their Use in Enteric Neuropathy Treatment | Non-Final OA | Children's Hospital Los Angeles |
| 18289361 | MANUFACTURING METHOD OF MEMORY T CELLS | Non-Final OA | Yasuhito Tokumoto |
| 18376459 | METHOD FOR PREPARING COMPOSITION COMPRISING MESENCHYMAL STEM CELL, EXTRACELLULAR VESICLE PRODUCED BY MESENCHYMAL STEM CELL, AND GROWTH FACTOR, COMPOSITION PREPARED BY THE METHOD, AND USE OF COMPOSITION FOR TREATING ARTHRITIS | Final Rejection | GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD. |
| 18235597 | PLATELETS-CONTAINING COMPOSITION AND PREPARATION PROCESS THEREOF | Non-Final OA | DAO-LUNG LIN |
| 18366527 | PROPHYLAXIS AND TREATMENT OF ORTHOPOX VIRUSES USING REGENERATIVE CELLS AND PRODUCTS THEREOF | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18260017 | CRISPNA FOR GENOME EDITING | Non-Final OA | FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD |
| 18343340 | VIRAL VECTOR DOSING PROTOCOLS | Non-Final OA | Selecta Biosciences, Inc. |
| 18007430 | APPLICATION OF MESENCHYMAL STEM CELLS IN PREPARATION OF DRUG FOR REPAIRING LUNG DAMAGE CAUSED BY COVID-19 | Non-Final OA | VCANBIO CELL & GENE ENGINEERING CORP., LTD |
| 17916134 | COMPOSITION | Final Rejection | INOCELLS B.V. |
| 17603459 | ANTI-INFLAMMAATORY AND ANTI-VIRAL COMPOSITION BASED ON PLACENTA-DERIVED EXTRACELLULAR VESICLE | Final Rejection | TS CELL BIO CO., LTD. |
| 17885088 | RECOMBINANT NUCLEIC ACID CONSTRUCT AND USE THEREOF | Non-Final OA | Pantherna Therapeutics GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy